Sunshine Biopharma acquires antibiotic marketing rights in Canada

Sunshine Biopharma has announced that it has acquired the marketing rights for two new generic antibiotics in Canada. The company signed a strategic agreement that will allow it to promote these products through its Canadian subsidiary, Nora Pharma. The antibiotics are expected to be launched within the next six to nine months, pending regulatory approval. This move comes as the global antibiotics market is projected to grow significantly in the coming years. In 2024, the market size was estimated at around $53.9 billion and is expected to increase to about $85.8 billion by 2033. This growth signifies a compound annual growth rate of 5.3%.